Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Japanese male or female~Exclusion Criteria:~* Has a history of invasive pneumococcal disease (IPD)~* Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid containing vaccine~* Has a known or suspected impairment of immunological function~* Has a history of congenital or acquired immunodeficiency~* Has or his/her mother has a documented human immunodeficiency virus (HIV) infection~* Has or his/her mother has a documented hepatitis B surface antigen-positive test~* Has known or history of functional or anatomic asplenia~* Has a history of autoimmune disease~* Has a known neurologic or cognitive behavioral disorder~* Has received a dose of any pneumococcal vaccine prior to study entry~* Has received a blood transfusion or blood products, including immunoglobulins

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- V114 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL subcutaneous injection of V114 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months of age.
- Pneumococcal 13-valent Conjugate Vaccine (PCV13) (Type: ACTIVE_COMPARATOR): Participants will receive a single 0.5 mL subcutaneous injection of PCV13 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).